MP0250 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses MP0250 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MP0250
- 1
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Molecular Partners AG (3)
Studies
Open first, then newest update. How each study uses MP0250 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCTerminatedPhase 1Molecular Partners AGNCT03418532Written as MP0250 DARPin® drug candidate, Osimertinib
- A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaCompletedPhase 1/2Molecular Partners AGNCT03136653Written as MP0250 plus BOR+DEX
- First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer PatientsCompletedPhase 1/2Molecular Partners AGNCT02194426Written as MP0250
Codes
What other systems call MP0250 · ClinicalTrials.gg INT000964
- NCI Thesaurus C117236VEGF/HGF-targeting DARPin MP0250One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C117236 | VEGF/HGF-targeting DARPin MP0250 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.